Replies to post #212835 on Biotech Values

[DewDiligence]

ENTA's actual milestone from ABBV for FDA approval of Mavyret is $40M (vs my estimate of $45-50M):

http://ir.enanta.com/news-releases/news-release-details/enanta-announces-us-fda-approval-abbvies-mavyrettm

Inasmuch as the total G/P approval milestones are known to be $80M—and $65M has been earned for approval in the EU ($25M) and US ($40M)—we now know that approval in Japan will bring a $15M milestone.

[DewDiligence]

ABBV/ENTA’s Maviret* approved in Canada:

https://finance.yahoo.com/news/abbvies-maviret-approved-health-canada-130300201.html

ENTA does not receive a milestone payment from ABBV for Maviret approval in Canada, but ENTA does get a $15M milestone payment from ABBV for approval in Japan, which is expected in the next two quarters.

*Note spelling, which is the same as the brand name in the EU but differs from the “Mavyret” brand name in the US.